Go to
JCI Insight
Citations to this article
Stefan Gross, … , Christoph Lengauer, Klaus P. Hoeflich
Published May 1, 2015
Citation Information: J Clin Invest. 2015;125(5):1780-1789. https://doi.org/10.1172/JCI76094.
Citation Information: J Clin Invest. 2015;125(5):1780-1789. https://doi.org/10.1172/JCI76094.
Abstract
Kinase inhibitors have played an increasingly prominent role in the treatment of cancer and other diseases. Currently, more than 25 oncology drugs that target kinases have been approved, and numerous additional therapeutics are in various stages of clinical evaluation. In this Review, we provide an in-depth analysis of activation mechanisms for kinases in cancer, highlight recent successes in drug discovery, and demonstrate the clinical impact of selective kinase inhibitors. We also describe the substantial progress that has been made in designing next-generation inhibitors to circumvent on-target resistance mechanisms, as well as ongoing strategies for combining kinase inhibitors in the clinic. Last, there are numerous prospects for the discovery of novel kinase targets, and we explore cancer immunotherapy as a new and promising research area for studying kinase biology.
Authors
Stefan Gross, Rami Rahal, Nicolas Stransky, Christoph Lengauer, Klaus P. Hoeflich
Total citations by year
Citation information
Citations to this article (206)
| Title and authors | Publication | Year |
|---|---|---|
|
Clear cell renal carcinoma essentially requires CDKL3 for oncogenesis
Ma L, Pang Z, Zhang H, Yang X, Zheng S, Chen Y, Ding W, Han Q, Zhang X, Cao L, Fei T, Wang Q, Gao D, He A, Hu KB, Li X, Sheng R |
Proceedings of the National Academy of Sciences of the United States of America | 2025 |
|
Transcriptomic analysis identifies B-lymphocyte kinase as a therapeutic target for desmoplastic small round cell tumor cancer stem cell-like cells
Magrath JW, Flinchum DA, Hartono AB, Sampath SS, O\u2019Grady TM, Baddoo M, Haoyang L, Xu X, Flemington EK, Lee SB |
Oncogenesis | 2024 |
|
Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer
Li W, Zhang K, Wang W, Liu Y, Huang J, Zheng M, Li L, Zhang X, Xu M, Chen G, Wang L, Zhang S |
Journal of experimental & clinical cancer research : CR | 2024 |
|
Novel meriolin derivatives activate the mitochondrial apoptosis pathway in the presence of antiapoptotic Bcl-2.
Schmitt L, Lechtenberg I, Drießen D, Flores-Romero H, Skowron MA, Sekeres M, Hoppe J, Krings KS, Llewellyn TR, Peter C, Stork B, Qin N, Bhatia S, Nettersheim D, Fritz G, García-Sáez AJ, Müller TJJ, Wesselborg S |
Cell Death Discovery | 2024 |
|
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors
Piha-Paul SA, Xu B, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon JA, Tsimberidou AM, Raghav K, Ajani JA, Conley AP, Mott F, Fan Y, Fan J, Peng P, Wang H, Ni S, Sun C, Qiang X, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM |
The oncologist | 2024 |
|
Cancer Therapy Resistance: Choosing Kinase Inhibitors
Dell\u2019Aversana C, Sarno F, Benedetti R, Megchelenbrink WL, Cappetta D |
Pharmaceutics | 2024 |
|
Germline MYOF1::WNK4 and VPS25::MYOF1 Chimeras Generated by the Constitutional Translocation t(17;19)(q21;p13) in Two Siblings With Myelodysplastic Syndrome.
Panagopoulos I, Andersen K, Stavseth V, Torkildsen S, Heim S, Tandsæther MR |
Cancer genomics & proteomics | 2024 |
|
Post-translational modifications: The potential ways for killing cancer stem cells
Han X, Qin H, Lu Y, Chen H, Yuan Z, Zhang Y, Yang X, Zheng L, Yan S |
Heliyon | 2024 |
|
A Review on Anaplastic Lymphoma Kinase (ALK) Rearrangements and Mutations: Implications for Gastric Carcinogenesis and Target Therapy.
Mesquita FP, Lima LB, da Silva EL, Souza PFN, de Moraes MEA, Burbano RMR, Montenegro RC |
Current protein & peptide science | 2024 |
|
Investigating druggable kinases for targeted therapy in retinoblastoma.
Jeyaprakash K, Kumaran M, Kim U, Santhi R, Muthukkaruppan V, Devarajan B, Vanniarajan A |
Journal of human genetics | 2024 |
|
Uncovering naringin's anticancer mechanisms in glioblastoma via molecular docking and network pharmacology approaches.
Tharamelveliyil Rajendran A, Dheeraj Rajesh G, Ashtekar H, Sairam A, Kumar P, Vadakkepushpakath AN |
Scientific reports | 2024 |
|
Proteomic and phosphoproteomic landscape of localized prostate cancer unveils distinct molecular subtypes and insights into precision therapeutics
Wang Z, Yu H, Bao W, Qu M, Wang Y, Zhang L, Liu X, Liu C, He M, Li J, Dong Z, Zhang Y, Yang B, Hou J, Xu C, Wang L, Li X, Gao X, Yang C |
Proceedings of the National Academy of Sciences of the United States of America | 2024 |
|
Pyrazine-based small molecule kinase inhibitors: clinical applications and patent review (2019–2023)
Alsfouk A |
Future Medicinal Chemistry | 2024 |
|
Vascular endothelial growth factor receptor 2 as a potential host target for the inhibition of enterovirus replication
Zhao X, Qiao R, Hao M, Xu L, Wang D, Lu Y, Li J, Wu J, Li Y, Cheng T, Zhang W, Zhao J, Wang P |
Journal of Virology | 2024 |
|
MIRO2 promotes cancer invasion and metastasis via MYO9B suppression of RhoA activity
Boulton DP, Hughes CJ, Vaira V, Del Gobbo A, Palleschi A, Locatelli M, Danis E, Raza M, Neumann AJ, Purdy SC, Lerma R, Meshki J, Ford HL, Prekeris R, Morrissey C, Caino MC |
Cell reports | 2024 |
|
Cryptochromes and UBP12/13 deubiquitinases antagonistically regulate DNA damage response in Arabidopsis
Hu Y, Rosado D, Lindbäck LN, Micko J, Pedmale UV |
2023 | |
|
LIMK2 promotes melanoma tumor growth and metastasis through G3BP1-ESM1 pathway-mediated apoptosis inhibition.
Malvi P, Reddy DS, Kumar R, Chava S, Burela S, Parajuli K, Zhang X, Wajapeyee N |
Oncogene | 2023 |
|
A targeted genetic modifier screen in Drosophila uncovers vulnerabilities in a genetically complex model of colon cancer
Datta I, Vassel T, Linkous B, Odum T, Drew C, Taylor A, Bangi E |
G3: Genes|Genomes|Genetics | 2023 |
|
Proteomic Characterization of Acute Myeloid Leukemia for Precision Medicine
Casado P, Cutillas PR |
Molecular & cellular proteomics : MCP | 2023 |
|
Design and Synthesis of Pyrazole-Based Macrocyclic Kinase Inhibitors Targeting BMPR2
Amrhein JA, Wang G, Berger BT, Berger LM, Kalampaliki AD, Krämer A, Knapp S, Hanke T |
ACS Medicinal Chemistry Letters | 2023 |
|
CMGC Kinases in Health and Cancer.
Chowdhury I, Dashi G, Keskitalo S |
Cancers | 2023 |
|
Small-molecule inhibitors of kinases in breast cancer therapy: recent advances, opportunities, and challenges
Bansal I, Pandey AK, Ruwali M |
Frontiers in pharmacology | 2023 |
|
Heterogeneity of the tumor immune microenvironment and clinical interventions.
Jin Z, Zhou Q, Cheng JN, Jia Q, Zhu B |
Frontiers of Medicine | 2023 |
|
Poor Generalization by Current Deep Learning Models for Predicting Binding Affinities of Kinase Inhibitors
Ong WJ, Kirubakaran P, Karanicolas J |
2023 | |
|
Lapatinib dysregulates HER2 signaling and impairs the viability of human uveal melanoma cells
Shu W, Wang JZ, Zhu X, Wang K, Cherepanoff S, Conway RM, Madigan MC, Lim LA, Zhu H, Zhu L, Murray M, Zhou F |
Journal of Cancer | 2023 |
|
Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy
Bravo MJ, Burgos-Molina AM, García-Aranda M, Redondo M, Téllez T |
Cancers | 2023 |
|
Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL)
Chirino A, Montoya S, Safronenka A, Taylor J |
Genes & development | 2023 |
|
A novel graph convolutional neural network for predicting interaction sites on protein kinase inhibitors in phosphorylation
F Wang, Y Chen, J Yang, T Akutsu |
Scientific Reports | 2022 |
|
Biomedical Engineering Technologies: Volume 2
A Rasooly, H Baker, M Ossandon |
2022 | |
|
Proteomic cellular signatures of kinase inhibitor-induced cardiotoxicity
Y Xiong, T Liu, T Chen, J Hansen, B Hu, Y Chen, G Jayaraman, S Schürer, D Vidovic, J Goldfarb, E Sobie, M Birtwistle, R Iyengar, H Li, E Azeloglu |
Scientific Data | 2022 |
|
Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors
F Fabro, M Lamfers, S Leenstra |
Cancers | 2022 |
|
Strategic Decoy Peptides Interfere with MSI1/AGO2 Interaction to Elicit Tumor Suppression Effects
Y Yang, A Lee, L Lin, Y Chen, P Huang, H Ma, Y Chen, W Lo, Y Lan, W Fang, C Wang, Y Liu, P Hsu, W Lin, C Li, M Chen, C Chien, M Wang |
Cancers | 2022 |
|
Choosing Kinase Inhibitors for Androgen Deprivation Therapy-Resistant Prostate Cancer
S Zhong, S Peng, Z Chen, Z Chen, J Luo |
Pharmaceutics | 2022 |
|
Identification of potent inhibitors of NEK7 protein using a comprehensive computational approach
M Aziz, S Ejaz, N Tamam, F Siddique, N Riaz, F Qais, S Chtita, J Iqbal |
Scientific Reports | 2022 |
|
Degraders: The Ultimate Weapon Against Amplified Driver Kinases in Cancer
P Torres-Ayuso, J Brognard |
Molecular pharmacology | 2022 |
|
Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study
B Tullemans, S Brouns, F Swieringa, S Sabrkhany, F van den Berkmortel, N Peters, P de Bruijn, S Koolen, J Heemskerk, M Aarts, M Kuijpers |
BMC Cancer | 2022 |
|
Phosphorylation of Yun is required for stem cell proliferation and tumorigenesis
Ren X, Zhao H, Shi L, Li Z, Kong R, Ma R, Jia L, Lu S, Wang J, Dong M, Wang Y, Li Z |
Cell Proliferation | 2022 |
|
Computational Model of Heterogeneity in Melanoma: Designing Therapies and Predicting Outcomes
Hodgkinson A, Trucu D, Lacroix M, Le Cam L, Radulescu O |
Frontiers in Oncology | 2022 |
|
In Silico, In Vitro, and Pharmacokinetic Studies of UBMC-4, a Potential Novel Compound for Treating against Trypanosoma cruzi
Bustamante C, Díez-Mejía AF, Arbeláez N, Soares MJ, Robledo SM, Ochoa R, Varela-M. RE, Marín-Villa M |
Pathogens | 2022 |
|
JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies.
Downes CE, McClure BJ, McDougal DP, Heatley SL, Bruning JB, Thomas D, Yeung DT, White DL |
Frontiers in Cell and Developmental Biology | 2022 |
|
Genome-wide analysis of genes encoding core components of the ubiquitin system during cerebral cortex development.
Bouron A, Fauvarque MO |
Molecular brain | 2022 |
|
Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways
Zhu Z, McGray AJ, Jiang W, Lu B, Kalinski P, Guo ZS |
Molecular Cancer | 2022 |
|
Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis
Carnero Contentti E, Correale J |
Drug design, development and therapy | 2022 |
|
Combination of Type I and II tyrosine kinase inhibitors—avapritinib and sunitinib—in refractory gastrointestinal stromal tumor after failure to multi-line therapy: a case report
Guo X, Huang S, Shi Y, Guan Z, Chen S, Feng Y, Xia Y, Zhang X |
Annals of translational medicine | 2022 |
|
Macrophage subsets and their role: co-relation with colony-stimulating factor-1 receptor and clinical relevance.
Yadav S, Priya A, Borade DR, Agrawal-Rajput R |
Immunologic research | 2022 |
|
Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries.
Montinaro A, Walczak H |
Cell Death and Differentiation | 2022 |
|
Radiotherapy-Related Gene Signature in Prostate Cancer.
Fortis SP, Goulielmaki M, Aubert N, Batsaki P, Ouzounis S, Cavouras D, Marodon G, Stokidis S, Gritzapis AD, Baxevanis CN |
Cancers | 2022 |
|
Bruton's Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis.
Garg N, Padron EJ, Rammohan KW, Goodman CF |
Journal of Clinical Medicine | 2022 |
|
CRISPR-based kinome-screening revealed MINK1 as a druggable player to rewire 5FU-resistance in OSCC through AKT/MDM2/p53 axis
Mohanty S, Mohapatra P, Shriwas O, Ansari SA, Priyadarshini M, Priyadarsini S, Rath R, Sultania M, Das Majumdar SK, Swain RK, Dash R |
Oncogene | 2022 |
|
Development and validation of a novel ubiquitination-related gene prognostic signature based on tumor microenvironment for colon cancer
Huang B, Deng W, Chen P, Mao Q, Chen H, Zhuo Z, Huang Z, Chen K, Huang J, Luo Y |
Translational cancer research | 2022 |
|
Novel kinome profiling technology reveals drug treatment is patient and 2D/3D model dependent in glioblastoma
Fabro F, Kannegieter NM, de Graaf EL, Queiroz K, Lamfers ML, Ressa A, Leenstra S |
Frontiers in Oncology | 2022 |
|
Kinase-Catalyzed Crosslinking and Immunoprecipitation (K-CLIP) to Explore Kinase-Substrate Pairs
Beltman RJ, Pflum MK |
2022 | |
|
βIII-tubulin suppression enhances the activity of Amuvatinib to inhibit cell proliferation in c-Met positive non-small cell lung cancer cells.
Brayford S, Duly A, Teo WS, Dwarte T, Gonzales-Aloy E, Ma Z, McVeigh L, Failes TW, Arndt GM, McCarroll JA, Kavallaris M |
Cancer Medicine | 2022 |
|
SAP30, an oncogenic driver of progression, poor survival, and drug resistance in neuroblastoma
Prathipati P, Pathania AS, Chaturvedi NK, Gupta SC, Byrareddy SN, Coulter DW, Challagundla KB |
2022 | |
|
Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition
Y Bai, JY Kim, B Bisunke, LA Jayne, JA Silvaroli, MS Balzer, M Gandhi, KM Huang, V Sander, J Prosek, RE Cianciolo, SD Baker, A Sparreboom, KD Jhaveri, K Susztak, A Bajwa, NS Pabla |
Kidney International | 2021 |
|
Ubiquitination of Nonhistone Proteins in Cancer Development and Treatment
X Zhang, T Meng, S Cui, L Feng, D Liu, Q Pang, P Wang |
Frontiers in Oncology | 2021 |
|
ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer
I Ferrarini, A Louie, L Zhou, WS El-Deiry |
Molecular cancer therapeutics | 2021 |
|
Inflammatory conversion of quiescent osteoblasts by metastatic breast cancer cells through pERK1/2 aggravates cancer-induced bone destruction
J Back, MN Nguyen, L Li, S Lee, I Lee, F Chen, L Gillinov, YH Chung, KD Alder, HK Kwon, KE Yu, CM Dussik, Z Hao, MJ Flores, Y Kim, IK Ibe, AM Munger, SW Seo, FY Lee |
Bone Research | 2021 |
|
Development of cell‐based high throughput luminescence assay for drug discovery in inhibiting OCT4/DNA‐PKcs and OCT4–MK2 interactions
IS Mohiuddin, SJ Wei, IH Yang, GM Martinez, S Yang, EJ Cho, KN Dalby, MH Kang |
Biotechnology and Bioengineering | 2021 |
|
Targeted mass-spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP kinase, and AKT signaling
JR Whiteaker, K Sharma, MA Hoffman, E Kuhn, L Zhao, AR Cocco, RM Schoenherr, JJ Kennedy, U Voytovich, C Lin, B Fang, K Bowers, G Whiteley, S Colantonio, W Bocik, R Roberts, T Hiltke, E Boja, H Rodriguez, F McCormick, M Holderfield, SA Carr, JM Koomen, AG Paulovich |
2021 | |
|
Targeting Protein Kinases in Blood Cancer: Focusing on CK1α and CK2
Z Spinello, A Fregnani, LQ Tubi, L Trentin, F Piazza, S Manni |
International journal of molecular sciences | 2021 |
|
Copy number aberrations drive kinase rewiring, leading to genetic vulnerabilities in cancer
D Memon, MB Gill, EK Papachristou, D Ochoa, CS DSantos, ML Miller, P Beltrao |
Cell Reports | 2021 |
|
Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
MV Suskil, KN Sultana, WO Elbezanti, OS Al-Odat, R Chitren, AK Tiwari, KB Challagundla, SK Srivastava, SC Jonnalagadda, T Budak-Alpdogan, MK Pandey |
International journal of molecular sciences | 2021 |
|
Heterogeneous Off-Target Effects of Ultra-Low Dose Dimethyl Sulfoxide (DMSO) on Targetable Signaling Events in Lung Cancer In Vitro Models
E Baldelli, M Subramanian, AM Alsubaie, G Oldaker, M Emelianenko, EE Gazzah, S Baglivo, KA Hodge, F Bianconi, V Ludovini, L Crino, EF Petricoin, M Pierobon |
International journal of molecular sciences | 2021 |
|
Human papillomavirus E6 and E7: What remains?
A Vats, O Trejo-Cerro, M Thomas, L Banks |
2021 | |
|
Excipient-Free Pure Drug Nanoparticles Fabricated by Microfluidic Hydrodynamic Focusing
RS Arzi, A Kay, Y Raychman, A Sosnik |
Pharmaceutics | 2021 |
|
How Far Are We from the Rapid Prediction of Drug Resistance Arising Due to Kinase Mutations?
M Erguven, T Karakulak, MK Diril, E Karaca |
ACS Omega | 2021 |
|
A mechanism for localized dynamics-driven activation in Bruton's tyrosine kinase
S Qiu, Y Liu, Q Li |
Royal Society Open Science | 2021 |
|
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial
AJ Wagner, PL Severson, AF Shields, A Patnaik, R Chugh, G Tinoco, G Wu, M Nespi, J Lin, Y Zhang, T Ewing, G Habets, EA Burton, B Matusow, J Tsai, G Tsang, R Shellooe, H Carias, K Chan, H Rezaei, L Sanftner, A Marimuthu, W Spevak, PN Ibrahim, K Inokuchi, O Alcantar, G Michelson, AC Tsiatis, C Zhang, G Bollag, JC Trent, WD Tap |
JAMA Oncology | 2021 |
|
Addiction to Golgi-resident PI4P synthesis in chromosome 1q21.3–amplified lung adenocarcinoma cells
L Shi, X Tan, X Liu, J Yu, N Bota-Rabassedas, Y Niu, J Luo, , C Zong, CJ Creighton, JS Glenn, J Wang, JM Kurie |
Proceedings of the National Academy of Sciences | 2021 |
|
Synthesis and Biological Evaluation of (S)-2-(Substituted arylmethyl)-1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a]indole-3-carboxamide Analogs and Their Synergistic Effect against PTEN-Deficient MDA-MB-468 Cells
YM Kwon, SH Kim, YS Jung, JH Kwak |
Pharmaceuticals (Basel, Switzerland) | 2021 |
|
Cooperative Blockade of CK2 and ATM Kinases Drives Apoptosis in VHL-Deficient Renal Carcinoma Cells through ROS Overproduction
S Giacosa, C Pillet, I Séraudie, L Guyon, Y Wallez, C Roelants, C Battail, B Evrard, F Chalmel, C Barette, E Soleilhac, MO Fauvarque, Q Franquet, C Sarrazin, N Peilleron, G Fiard, JA Long, JL Descotes, C Cochet, O Filhol |
Cancers | 2021 |
|
Fasting-Induced Upregulation of MKP-1 Modulates the Hepatic Response to Feeding
J Sellers, A Brooks, S Fernando, G Westenberger, S Junkins, S Smith, K Min, A Lawan |
Nutrients | 2021 |
|
Mechanisms of Pharmaceutical Therapy and Drug Resistance in Esophageal Cancer
C Mao, X Zeng, C Zhang, Y Yang, X Xiao, S Luan, Y Zhang, Y Yuan |
Frontiers in Cell and Developmental Biology | 2021 |
|
Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent Kinase
S Rana, JR Mallareddy, S Singh, L Boghean, A Natarajan |
Cancers | 2021 |
|
Kinase Inhibitors’ Effects on Innate Immunity in Solid Cancers
C Peng, K Rabold, WJ Mulder, M Jaeger, RT Netea-Maier |
Cancers | 2021 |
|
ChiTaH: a fast and accurate tool for identifying known human chimeric sequences from high-throughput sequencing data
R Detroja, A Gorohovski, O Giwa, G Baum, M Frenkel-Morgenstern |
2021 | |
|
CSNK2 in cancer: pathophysiology and translational applications
SW Strum, L Gyenis, DW Litchfield |
British Journal of Cancer | 2021 |
|
Screening and Identification of Lujo Virus Inhibitors Using a Recombinant Reporter Virus Platform
SR Welch, JR Spengler, SC Genzer, P Chatterjee, M Flint, É Bergeron, JM Montgomery, ST Nichol, CG Albariño, CF Spiropoulou |
Viruses | 2021 |
|
Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication
G Garcia, A Sharma, A Ramaiah, C Sen, A Purkayastha, DB Kohn, MS Parcells, S Beck, H Kim, MA Bakowski, MG Kirkpatrick, L Riva, KC Wolff, B Han, C Yuen, D Ulmert, PK Purbey, P Scumpia, N Beutler, TF Rogers, AK Chatterjee, G Gabriel, R Bartenschlager, B Gomperts, CN Svendsen, UA Betz, RD Damoiseaux, V Arumugaswami |
Cell Reports | 2021 |
|
Short loop functional commonality identified in leukaemia proteome highlights crucial protein sub-networks
SS Chung, JC Ng, A Laddach, NS Thomas, F Fraternali |
2021 | |
|
Passive Diffusion vs Active pH-Dependent Encapsulation of Tyrosine Kinase Inhibitors Vandetanib and Lenvatinib into Folate-Targeted Ferritin Delivery System
Z Skubalova, S Rex, M Sukupova, M Zahalka, P Skladal, J Pribyl, H Michalkova, A Weerasekera, V Adam, Z Heger |
International Journal of Nanomedicine | 2021 |
|
Synthesis of illudalic acid and analogous phosphatase inhibitors
H Fulo, N Rueb, R Gaston, P Batsomboon, K Ahmed, A Barrios, G Dudley |
Organic & Biomolecular Chemistry | 2021 |
|
Inhibition of the CDK9‒cyclin T1 protein‒protein interaction as a new approach against triple-negative breast cancer
S Cheng, Y Qu, J Wu, G Yang, H Liu, W Wang, Q Huang, F Chen, G Li, C Wong, V Wong, D Ma, C Leung |
Acta pharmaceutica Sinica. B | 2021 |
|
Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target.
Islam S, Wang S, Bowden N, Martin J, Head R |
British Journal of Clinical Pharmacology | 2021 |
|
Mixed lineage kinase 3 inhibition induces T cell activation and cytotoxicity
S Kumar, SK Singh, N Viswakarma, G Sondarva, RS Nair, P Sethupathi, SC Sinha, R Emmadi, K Hoskins, O Danciu, GR Thatcher, B Rana, A Rana |
Proceedings of the National Academy of Sciences | 2020 |
|
A kinome-wide screen identifies a CDKL5-SOX9 regulatory axis in epithelial cell death and kidney injury
JY Kim, Y Bai, LA Jayne, RD Hector, AK Persaud, SS Ong, S Rojesh, R Raj, MJ Feng, S Chung, RE Cianciolo, JW Christman, MJ Campbell, DS Gardner, SD Baker, A Sparreboom, R Govindarajan, H Singh, T Chen, M Poi, K Susztak, SR Cobb, NS Pabla |
Nature Communications | 2020 |
|
Involvement of the CDKL5-SOX9 signaling axis in rhabdomyolysis-associated acute kidney injury
JY Kim, Y Bai, LA Jayne, RE Cianciolo, A Bajwa, NS Pabla |
American journal of physiology. Renal physiology | 2020 |
|
Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis
H Zhou, MA Blevins, JY Hsu, D Kong, MD Galbraith, A Goodspeed, R Culp-Hill, MU Oliphant, D Ramirez, L Zhang, J Trinidad-Pineiro, LM Griner, R King, E Barnaeva, X Hu, NT Southall, M Ferrer, DL Gustafson, DP Regan, A D'Alessandro, JC Costello, S Patnaik, J Marugan, R Zhao, HL Ford |
Cancer research | 2020 |
|
The role of ubiquitination in tumorigenesis and targeted drug discovery
L Deng, T Meng, L Chen, W Wei, P Wang |
Signal Transduction and Targeted Therapy | 2020 |
|
Auto In Silico Ligand Directing Evolution to Facilitate the Rapid and Efficient Discovery of Drug Lead
F Wu, L Zhuo, F Wang, W Huang, G Hao, G Yang |
iScience | 2020 |
|
Targeting Crucial Host Factors of SARS-CoV-2
AM Tharappel, SK Samrat, Z Li, H Li |
ACS Infectious Diseases | 2020 |
|
Comparative Proton and Photon Irradiation Combined with Pharmacological Inhibitors in 3D Pancreatic Cancer Cultures
J Görte, E Beyreuther, EH Danen, N Cordes |
Cancers | 2020 |
|
MASTL: A novel therapeutic target for Cancer Malignancy
I Fatima, AB Singh, P Dhawan |
Cancer Medicine | 2020 |
|
IκB kinase-ε-mediated phosphorylation triggers IRF-1 degradation in breast cancer cells
AL Remoli, M Sgarbanti, E Perrotti, M Acchioni, R Orsatti, C Acchioni, A Battistini, R Clarke, G Marsili |
Neoplasia (New York, N.Y.) | 2020 |
|
Identification of Sphingosine Kinase-1 Inhibitors from Bioactive Natural Products Targeting Cancer Therapy
DS Jairajpuri, T Mohammad, K Adhikari, P Gupta, GM Hasan, MF Alajmi, T Rehman, A Hussain, I Hassan |
ACS Omega | 2020 |
|
Landscape of drug-resistance mutations in kinase regulatory hotspots
P Kim, H Li, J Wang, Z Zhao |
Briefings in Bioinformatics | 2020 |
|
NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target
A Gambella, R Senetta, G Collemi, SG Vallero, M Monticelli, F Cofano, P Zeppa, D Garbossa, A Pellerino, R Rudà, R Soffietti, F Fagioli, M Papotti, P Cassoni, L Bertero |
International journal of molecular sciences | 2020 |
|
Marine alkaloid monanchoxymycalin C: a new specific activator of JNK1/2 kinase with anticancer properties
SA Dyshlovoy, M Kaune, M Kriegs, J Hauschild, T Busenbender, LK Shubina, TN Makarieva, K Hoffer, C Bokemeyer, M Graefen, VA Stonik, G von Amsberg |
Scientific Reports | 2020 |
|
Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer Z Zhu, L Ling, L Qi, Y Chong, L Xue |
OncoTargets and therapy | 2020 |
|
Recurrent Fusion of the GRB2 Associated Binding Protein 1 ( GAB1 ) Gene With ABL Proto-oncogene 1 ( ABL1 ) in Benign Pediatric Soft Tissue Tumors
I Panagopoulos, L Gorunova, K Andersen, S Tafjord, M LUND-IVERSEN, IN Lobmaier, F Micci, S Heim |
Cancer genomics & proteomics | 2020 |
|
Downregulation of PUMA underlies resistance to FGFR1 inhibitors in the stem cell leukemia/lymphoma syndrome
Y Liu, B Cai, Y Chong, H Zhang, CA Kemp, S Lu, CS Chang, M Ren, JK Cowell, T Hu |
Cell Death and Disease | 2020 |
|
Characterization of GRK5 as a novel regulator of rhabdomyosarcoma tumor cell growth and self-renewal
T Pham, K Robinson, T Vleeshouwer-Neumann, JE Annis, EY Chen |
Oncotarget | 2020 |
|
Targeting disseminated estrogen-receptor-positive breast cancer cells in bone marrow
JM Buschhaus, BA Humphries, SS Eckley, TH Robison, AC Cutter, S Rajendran, HR Haley, AS Bevoor, KE Luker, GD Luker |
Oncogene | 2020 |
|
PIN1 Provides Dynamic Control of MYC in Response to Extrinsic Signals
GM Cohn, DF Liefwalker, EM Langer, RC Sears |
Frontiers in Cell and Developmental Biology | 2020 |
|
Structural and Functional Overview of TEAD4 in Cancer Biology M Chen, B Huang, L Zhu, K Chen, M Liu, C Zhong |
OncoTargets and therapy | 2020 |
|
Characterization of Kinase Expression Related to Increased Migration of PC-3M Cells Using Global Comparative Phosphoproteome Analysis
Y Gao, YS Ha, TG Kwon, YC Cho, S Lee, JN Lee |
Cancer genomics & proteomics | 2020 |
|
A novel screening approach comparing kinase activity of small molecule inhibitors with similar molecular structures and distinct biologic effects in triple-negative breast cancer to identify targetable signaling pathways
MD Matossian, HE Burks, S Elliott, VT Hoang, WJ Zuercher, C Wells, DH Drewry, N Kapadia, T Chang, T Yan, GO Windsor, K Nguyen, F Fang, KP Nephew, A Buechlein, DB Rusch, RA Sabol, DA Ucar, J Zabaleta, L Miele, BA Bunnell, BM Collins-Burow, ME Burow |
Anti-Cancer Drugs | 2020 |
|
Oncogenic mutations within the β3‐αC loop of EGFR / ERBB2 / BRAF / MAP2K1 predict response to therapies
B Zhang, Y Chen, P Dai, H Yu, J Ma, C Chen, Y Zhang, Y Guan, R Chen, T Liu, J Wang, L Yang, X Yi, X Xia, H Ma |
Molecular Genetics & Genomic Medicine | 2020 |
|
Effects of Glycyrrhetic Acid on Human Chronic Myelogenous Leukemia Cells
H ÇİFTÇİ |
2020 | |
|
Ellagic Acid Controls Cell Proliferation and Induces Apoptosis in Breast Cancer Cells via Inhibition of Cyclin-Dependent Kinase 6
M Yousuf, A Shamsi, P Khan, M Shahbaaz, MF AlAjmi, A Hussain, GM Hassan, A Islam, QM Haque, I Hassan |
International journal of molecular sciences | 2020 |
|
Emerging roles of the αC‐β4 loop in protein kinase structure, function, evolution, and disease
W Yeung, Z Ruan, N Kannan |
IUBMB Life | 2020 |
|
Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome
M Labots, TV Pham, RJ Honeywell, JC Knol, R Beekhof, R de Goeij-de Haas, H Dekker, M Neerincx, SR Piersma, JC van der Mijn, DL van der Peet, MR Meijerink, GJ Peters, NC van Grieken, CR Jiménez, HM Verheul |
Cancers | 2020 |
|
CK1α-targeting inhibits primary and metastatic colorectal cancer in vitro, ex vivo, in cell-line-derived and patient-derived tumor xenograft mice models
F Ren, J Zhu, K Li, Y Cheng, X Zhu |
Translational cancer research | 2020 |
|
Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia
PJ Sung, M Sugita, H Koblish, AE Perl, M Carroll |
Blood Advances | 2019 |
|
Small molecules as theranostic agents in cancer immunology
J Li, JV Valkenburgh, X Hong, PS Conti, X Zhang, K Chen |
Theranostics | 2019 |
|
FGF19–FGFR4 Signaling in Hepatocellular Carcinoma
A Raja, I Park, F Haq, SM Ahn |
Cells | 2019 |
|
Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors
Y Sun, L Yang, X Hao, Y Liu, J Zhang, Z Ning, Y Shi |
Journal of Hematology & Oncology | 2019 |
|
Neuropilin-1 peptide-like ligands with proline mimetics, tested using the improved chemiluminescence affinity detection method
AK Puszko, P Sosnowski, D Tymecka, F Raynaud, O Hermine, Y Lepelletier, A Misicka |
MedChemComm | 2019 |
|
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer
NG Nickols, R Nazarian, SG Zhao, V Tan, V Uzunangelov, Z Xia, R Baertsch, E Neeman, AC Gao, GV Thomas, L Howard, AM Hoedt, J Stuart, T Goldstein, K Chi, ME Gleave, JN Graff, TM Beer, JM Drake, CP Evans, R Aggarwal, A Foye, FY Feng, EJ Small, WJ Aronson, SJ Freedland, ON Witte, J Huang, JJ Alumkal, RE Reiter, MB Rettig |
Prostate Cancer and Prostatic Diseases | 2019 |
|
Evaluation of Protein Kinase Inhibitors with PLK4 Cross-Over Potential in a Pre-Clinical Model of Cancer
A Suri, AW Bailey, MT Tavares, H Gunosewoyo, CP Dyer, AT Grupenmacher, DR Piper, RA Horton, T Tomita, AP Kozikowski, SM Roy, ST Sredni |
International journal of molecular sciences | 2019 |
|
New Series of Thiazole Derivatives: Synthesis, Structural Elucidation, Antimicrobial Activity, Molecular Modeling and MOE Docking
I Althagafi, N El-Metwaly, TA Farghaly |
Molecules (Basel, Switzerland) | 2019 |
|
Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy
M García-Aranda, M Redondo |
International journal of molecular sciences | 2019 |
|
Fibrillary Glomerulonephritis: An Update
JL Rosenstock, GS Markowitz |
Kidney International Reports | 2019 |
|
Emerging Trends and Promises in Orofacial Cancers
TA Mitsiadis |
Frontiers in physiology | 2019 |
|
Systematic computational identification of promiscuity cliff pathways formed by inhibitors of the human kinome
F Miljković, M Vogt, J Bajorath |
Journal of Computer-Aided Molecular Design | 2019 |
|
Identifying Candidate Druggable Targets in Canine Cancer Cell Lines Using Whole-Exome Sequencing
S Das, R Idate, KE Cronise, DL Gustafson, DL Duval |
Molecular cancer therapeutics | 2019 |
|
Testing algorithm for identification of patients with TRK fusion cancer
F Penault-Llorca, ER Rudzinski, AR Sepulveda |
Journal of clinical pathology | 2019 |
|
Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
S Fernandez, V Desplat, A Villacreces, AV Guitart, N Milpied, A Pigneux, I Vigon, JM Pasquet, PY Dumas |
International journal of molecular sciences | 2019 |
|
Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods
BJ Haas, A Dobin, B Li, N Stransky, N Pochet, A Regev |
Genome biology | 2019 |
|
Activation and function of receptor tyrosine kinases in human clear cell renal cell carcinomas
Q Zhang, JH Liu, JL Liu, CT Qi, L Yan, Y Chen, Q Yu |
BMC Cancer | 2019 |
|
High-Throughput Assessment of Kinome-wide Activation States
T Schmidlin, DO Debets, CA van Gelder, KE Stecker, S Rontogianni, BL van den Eshof, K Kemper, EH Lips, M van den Biggelaar, DS Peeper, AJ Heck, M Altelaar |
Cell Systems | 2019 |
|
Targeting ERK beyond the boundaries of the kinase active site in melanoma
RM Sammons, R Ghose, KY Tsai, KN Dalby |
Molecular Carcinogenesis | 2019 |
|
Evaluation of binding and inhibition mechanism of dietary phytochemicals with sphingosine kinase 1: Towards targeted anticancer therapy
P Gupta, T Mohammad, R Dahiya, S Roy, OM Noman, MF Alajmi, A Hussain, I Hassan |
Scientific Reports | 2019 |
|
Targeting the non-canonical roles of PCNA modifies and increases the response to targeted anti-cancer therapy
CK Søgaard, A Nepal, V Petrovic, A Sharma, NB Liabakk, TS Steigedal, M Otterlei |
Oncotarget | 2019 |
|
Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer
Yunhua Liu, Hanchen Xu, Kevin Van der Jeught, Yujing Li, Sheng Liu, Lu Zhang, Yuanzhang Fang, Xinna Zhang, Milan Rodovich, Bryan Schneider, Xiaoming He, Cheng Huang, Chi Zhang, Jun Wan, Guang Ji, Xiongbin Lu |
Journal of Clinical Investigation | 2018 |
|
Targeting Cyclin D-CDK4/6 sensitizes immune-refractory cancer by blocking the SCP3-NANOG axis
SJ Oh, H Cho, S Kim, KH Noh, KH Song, HJ Lee, SR Woo, S Kim, CH Choi, JY Chung, SM Hewitt, JH Kim, S Baek, KM Lee, C Yee, HC Park, TW Kim |
Cancer research | 2018 |
|
Role of Bruton’s tyrosine kinase in B cells and malignancies
SP Singh, F Dammeijer, RW Hendriks |
Molecular Cancer | 2018 |
|
Signaling through non-membrane nuclear phosphoinositide binding proteins in human health and disease
JM Bryant, RD Blind |
Journal of lipid research | 2018 |
|
The impact of phosphatases on proliferative and survival signaling in cancer
G Narla, J Sangodkar, CB Ryder |
Cellular and Molecular Life Sciences | 2018 |
|
Integrative landscape of dysregulated signaling pathways of clinically distinct pancreatic cancer subtypes
M Sinkala, N Mulder, DP Martin |
Oncotarget | 2018 |
|
The Human Replicative Helicase, the CMG Complex, as a Target for Anti-cancer Therapy
YS Seo, YH Kang |
Frontiers in Molecular Biosciences | 2018 |
|
Targeting tumour microenvironment by tyrosine kinase inhibitor
HY Tan, N Wang, W Lam, W Guo, Y Feng, YC Cheng |
Molecular Cancer | 2018 |
|
High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-ALL
DR Perez, CK Nickl, A Waller, C Delgado-Martin, T Woods, ND Sharma, ML Hermiston, ML Loh, SP Hunger, SS Winter, A Chigaev, B Edwards, LA Sklar, K Matlawska-Wasowska |
SLAS Discovery | 2018 |
|
PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer
AE Fearon, EP Carter, NS Clayton, EH Wilkes, AM Baker, E Kapitonova, BA Bakhouche, Y Tanner, J Wang, E Gadaleta, C Chelala, KM Moore, JF Marshall, J Chupin, P Schmid, JL Jones, M Lockley, PR Cutillas, RP Grose |
Cell Reports | 2018 |
|
Combination Kinase Inhibitor Treatment Suppresses Rift Valley Fever Virus Replication
T Bell, V Espina, L Lundberg, C Pinkham, A Brahms, B Carey, SC Lin, B Dahal, C Woodson, C de la Fuente, L Liotta, C Bailey, K Kehn-Hall |
Viruses | 2018 |
|
Detection of the Cell Cycle-Regulated Negative Feedback Phosphorylation of Mitogen-Activated Protein Kinases in Breast Carcinoma using Nanofluidic Proteomics
Y Urasaki, RR Fiscus, TT Le |
Scientific Reports | 2018 |
|
RNA-modifying proteins as anticancer drug targets
PA Boriack-Sjodin, S Ribich, RA Copeland |
Nature Reviews Drug Discovery | 2018 |
|
Identification of new inhibitors against human Great wall kinase using in silico approaches
U Ammarah, A Kumar, R Pal, NC Bal, G Misra |
Scientific Reports | 2018 |
|
Rapid expansion in the WAVE bioreactor of clinical scale cells for tumor immunotherapy
Y Meng, J Sun, T Hu, Y Ma, T Du, C Kong, G Zhang, T Yu, H Piao |
Human Vaccines & Immunotherapeutics | 2018 |
|
Protein kinase D displays intrinsic Tyr autophosphorylation activity: insights into mechanism and regulation
M Cobbaut, R Derua, PJ Parker, E Waelkens, V Janssens, JV Lint |
FEBS Letters | 2018 |
|
Overcoming Resistance to Targeted Anticancer Therapies through Small-Molecule-Mediated MEK Degradation
J Peh, MW Boudreau, HM Smith, PJ Hergenrother |
Cell Chemical Biology | 2018 |
|
Integration of protein phosphorylation, acetylation, and methylation data sets to outline lung cancer signaling networks
M Grimes, B Hall, L Foltz, T Levy, K Rikova, J Gaiser, W Cook, E Smirnova, T Wheeler, NR Clark, A Lachmann, B Zhang, P Hornbeck, A Maayan, M Comb |
Science signaling | 2018 |
|
Recent advances in precision oncology research
AM Bode, Z Dong |
npj Precision Oncology | 2018 |
|
Repurposing of Kinase Inhibitors as Broad-Spectrum Antiviral Drugs
S Schor, S Einav |
DNA and Cell Biology | 2018 |
|
Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients
BM Tullemans, M Nagy, S Sabrkhany, AW Griffioen, MG oude Egbrink, M Aarts, JW Heemskerk, MJ Kuijpers |
Frontiers in Cardiovascular Medicine | 2018 |
|
Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models
N Pinto, SD Prokopec, F Vizeacoumar, K Searle, M Lowerison, KM Ruicci, J Yoo, K Fung, D MacNeil, JC Lacefield, HS Leong, JS Mymryk, JW Barrett, A Datti, PC Boutros, AC Nichols, A Ahmad |
PloS one | 2018 |
|
Measuring the Global Substrate Specificity of Mycobacterial Serine Hydrolases Using a Library of Fluorogenic Ester Substrates
B Bassett, B Waibel, A White, H Hansen, D Stephens, A Koelper, EM Larsen, C Kim, A Glanzer, LD Lavis, GC Hoops, RJ Johnson |
ACS Infectious Diseases | 2018 |
|
A SMAP in the face for cancer
Shirish Shenolikar |
Journal of Clinical Investigation | 2017 |
|
A new cancer therapy based on activation of a tumor suppressor protein
Jaya Sangodkar, Rita Tohme, Abbey Perl, Janna Kiselar, David B. Kastrinsky, NIlesh Zaware, Sudeh Izadmehr, Sahar Mazhar, Danica Wiredja, Caitlin O'Connor, Divya Hoon, Neil S. Dhawan, Daniela Schlatzer, Shen Yao, Daniel Leonard, Alain Borczuk, Giridharan Gokulrangan, Lifu Wang, Elena Svenson, Caroline Farrington, Eric Yuan, Rita A. Avelar, Agnes Stachnik, Blake Smith, Vickram Gidwani, Heather Melville, Daniel McQuaid, Kimberly McClinch, ZhiZhi Wang, Alice C. Levine, Rosalie C. Sears, Edward Chen, Qiaonan Duan, Manish Datt, Shozeb Haider, Avi Ma'ayan, Analisa DiFeo, Neelesh Sharma, Matthew Galsky, David Brautigan, Yiannis Ioannou, Wenqing Xu, Mark Chance, Michael Ohlmeyer, Goutham Narla |
Journal of Clinical Investigation | 2017 |
|
Marburg- and Ebolaviruses: From Ecosystems to Molecules
E Mühlberger, LL Hensley, JS Towner |
2017 | |
|
Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models
WK Decker, RF da Silva, MH Sanabria, LS Angelo, F Guimarães, BM Burt, F Kheradmand, S Paust |
Frontiers in immunology | 2017 |
|
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don’t Forget the Fuel
M Irving, RV de Silly, K Scholten, N Dilek, G Coukos |
Frontiers in immunology | 2017 |
|
A Large-Scale RNAi Screen Identifies SGK1 as a Key Survival Kinase for GBM Stem Cells
S Kulkarni, S Goel-Bhattacharya, S Sengupta, BH Cochran |
Molecular cancer research : MCR | 2017 |
|
Tyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functions
A Borriello, I Caldarelli, D Bencivenga, E Stampone, S Perrotta, A Oliva, FD Ragione |
Oncotarget | 2017 |
|
Troponin through the looking-glass: emerging roles beyond regulation of striated muscle contraction
JR Johnston, PB Chase, JR Pinto |
Oncotarget | 2017 |
|
2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
PL Sulkowski, CD Corso, ND Robinson, SE Scanlon, KR Purshouse, H Bai, Y Liu, RK Sundaram, DC Hegan, NR Fons, GA Breuer, Y Song, K Mishra-Gorur, HM de Feyter, RA de Graaf, YV Surovtseva, M Kachman, S Halene, M Günel, PM Glazer, RS Bindra |
Science Translational Medicine | 2017 |
|
Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice
CC Pai, LT Khuat, M Chen, WJ Murphy, M Abedi |
Biology of Blood and Marrow Transplantation | 2017 |
|
Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models
R Chilà, TH G., G Abbadessa, M Broggini, G Damia |
Translational oncology | 2017 |
|
Applications of chemogenomic library screening in drug discovery
LH Jones, ME Bunnage |
Nature Reviews Drug Discovery | 2017 |
|
Carboxylate derivatives of tributyltin (IV) complexes as anticancer and antileishmanial agents
D Waseem, AF Butt, I Haq, MH Bhatti, GM Khan |
DARU Journal of Pharmaceutical Sciences | 2017 |
|
Characterization of Covalent-Reversible EGFR Inhibitors
S Smith, M Keul, J Engel, D Basu, S Eppmann, D Rauh |
ACS Omega | 2017 |
|
Heat-shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF
JD Konda, M Olivero, D Musiani, S Lamba, MF di Renzo |
Molecular Oncology | 2017 |
|
An Updated Review on Marine Anticancer Compounds: The Use of Virtual Screening for the Discovery of Small-Molecule Cancer Drugs
V Ruiz-Torres, J Encinar, M Herranz-López, A Pérez-Sánchez, V Galiano, E Barrajón-Catalán, V Micol |
Molecules (Basel, Switzerland) | 2017 |
|
A potent series targeting the malarial cGMP-dependent protein kinase clears infection and blocks transmission
DA Baker, LB Stewart, JM Large, PW Bowyer, KH Ansell, MB Jiménez-Díaz, ME Bakkouri, K Birchall, KJ Dechering, NS Bouloc, PJ Coombs, D Whalley, DJ Harding, E Smiljanic-Hurley, MC Wheldon, EM Walker, JT Dessens, MJ Lafuente, LM Sanz, FJ Gamo, SB Ferrer, R Hui, T Bousema, I Angulo-Barturén, AT Merritt, SL Croft, WE Gutteridge, CA Kettleborough, SA Osborne |
Nature Communications | 2017 |
|
Progress towards a public chemogenomic set for protein kinases and a call for contributions
DH Drewry, CI Wells, DM Andrews, R Angell, H Al-Ali, AD Axtman, SJ Capuzzi, JM Elkins, P Ettmayer, M Frederiksen, O Gileadi, N Gray, A Hooper, S Knapp, S Laufer, U Luecking, M Michaelides, S Müller, E Muratov, RA Denny, KS Saikatendu, DK Treiber, WJ Zuercher, TM Willson, A Duensing |
PloS one | 2017 |
|
Kinase Inhibitors: The Reality Behind the Success
JY Jeon, A Sparreboom, SD Baker |
Clinical Pharmacology & Therapeutics | 2017 |
|
Neuro-ophthalmic side effects of molecularly targeted cancer drugs
MT Bhatti, AK Salama |
Eye | 2017 |
|
Functional phosphatome requirement for protein homeostasis, networked mitochondria, and sarcomere structure in C. elegans muscle: Muscle functional phosphatome
S Lehmann, JJ Bass, TF Barratt, MZ Ali, NJ Szewczyk |
Journal of Cachexia, Sarcopenia and Muscle | 2017 |
|
Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo
D Schnerch, J Schüler, M Follo, J Felthaus, D Wider, K Klingner, C Greil, J Duyster, M Engelhardt, R Wäsch |
Oncotarget | 2017 |
|
Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: Results from a phase I study
JM Xu, Y Wang, YL Chen, R Jia, J Li, JF Gong, J Li, C Qi, Y Hua, CR Tan, J Wang, K Li, Y Sai, F Zhou, YX Ren, WG Qing, H Jia, WG Su, L Shen |
Oncotarget | 2017 |
|
Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications
HP Shih, X Zhang, AM Aronov |
Nature Reviews Drug Discovery | 2017 |
|
Reproducible Bioconductor workflows using browser-based interactive notebooks and containers
R Almugbel, LH Hung, J Hu, A Almutairy, N Ortogero, Y Tamta, KY Yeung |
Journal of the American Medical Informatics Association : JAMIA | 2017 |
|
Targeting Aberrant p70S6K Activation for Estrogen Receptor–Negative Breast Cancer Prevention
X Wang, J Yao, J Wang, Q Zhang, SW Brady, B Arun, VL Seewaldt, D Yu |
Cancer prevention research (Philadelphia, Pa.) | 2017 |
|
A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis
S Galbán, AA Apfelbaum, C Espinoza, K Heist, H Haley, K Bedi, M Ljungman, CJ Galbán, GD Luker, MV Dort, BD Ross |
Molecular cancer therapeutics | 2017 |
|
Comprehensive Analysis of Cancer-Proteogenome to Identify Biomarkers for the Early Diagnosis and Prognosis of Cancer
HD Shukla |
Proteomes | 2017 |
|
Spatial competition constrains resistance to targeted cancer therapy
K Bacevic, R Noble, A Soffar, OW Ammar, B Boszonyik, S Prieto, C Vincent, ME Hochberg, L Krasinska, D Fisher |
Nature Communications | 2017 |
|
Ubiquitin ligases in oncogenic transformation and cancer therapy
D Senft, J Qi, ZA Ronai |
Nature Reviews Cancer | 2017 |
|
New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness
I Corraliza-Gorjón, B Somovilla-Crespo, S Santamaria, JA Garcia-Sanz, L Kremer |
Frontiers in immunology | 2017 |
|
Design, Synthesis, and Biological Evaluation of Novel 1,3,4-Thiadiazole Derivatives as Potential Antitumor Agents against Chronic Myelogenous Leukemia: Striking Effect of Nitrothiazole Moiety
M Altıntop, H Ciftci, M Radwan, B Sever, Z Kaplancıklı, T Ali, R Koga, M Fujita, M Otsuka, A Özdemir |
Molecules (Basel, Switzerland) | 2017 |
|
Defined, serum/feeder-free conditions for expansion and drug screening of primary B-acute lymphoblastic leukemia
Z Jiang, D Wu, W Ye, J Weng, P Lai, P Shi, X Guo, G Huang, Q Deng, Y Tang, H Zhao, S Cui, S Lin, S Wang, B Li, Q Wu, Y Li, P Liu, D Pei, X Du, Y Yao, P Li |
Oncotarget | 2017 |
|
A potent, selective, and orally bioavailable inhibitor of the protein-tyrosine phosphatase PTP1B improves insulin and leptin signaling in animal models
N Krishnan, KF Konidaris, G Gasser, NK Tonks |
The Journal of biological chemistry | 2017 |
|
Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights
PP Zheng, J Li, JM Kros |
Medicinal Research Reviews | 2017 |
|
Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma
ST Sredni, AW Bailey, A Suri, R Hashizume, X He, N Louis, T Gokirmak, DR Piper, DM Watterson, T Tomita |
Oncotarget | 2017 |
|
Antagonizing STAT5B dimerization with an osmium complex
LJ Liu, W Wang, TS Kang, JX Liang, C Liu, DW Kwong, VK Wong, DL Ma, CH Leung |
Scientific Reports | 2016 |
|
System-Wide Modulation of HECT E3 Ligases with Selective Ubiquitin Variant Probes
W Zhang, KP Wu, MA Sartori, HB Kamadurai, A Ordureau, C Jiang, PY Mercredi, R Murchie, J Hu, A Persaud, M Mukherjee, N Li, A Doye, JR Walker, Y Sheng, Z Hao, Y Li, KR Brown, E Lemichez, J Chen, Y Tong, JW Harper, J Moffat, D Rotin, BA Schulman, SS Sidhu |
Molecular Cell | 2016 |
|
RANK-RANKL interactions are involved in cell adhesion-mediated drug resistance in multiple myeloma cell lines
M Tsubaki, T Takeda, M Yoshizumi, E Ueda, T Itoh, M Imano, T Satou, S Nishida |
Tumor Biology | 2016 |
|
Design, synthesis, crystallization and biological evaluation of new symmetrical biscationic compounds as selective inhibitors of human Choline Kinase α1 (ChoKα1)
S Schiaffino-Ortega, E Baglioni, E Mariotto, R Bortolozzi, L Serrán-Aguilera, P Ríos-Marco, MP Carrasco-Jimenez, MA Gallo, R Hurtado-Guerrero, C Marco, G Basso, G Viola, A Entrena, LC López-Cara |
Scientific Reports | 2016 |
|
Discovering and understanding oncogenic gene fusions through data intensive computational approaches
NS Latysheva, MM Babu |
Nucleic Acids Research | 2016 |
|
Chemical Methods for Encoding and Decoding of Posttranslational Modifications
KN Chuh, AR Batt, MR Pratt |
Cell Chemical Biology | 2016 |
|
Multi-scale Modeling in Clinical Oncology: Opportunities and Barriers to Success
TE Yankeelov, G An, O Saut, EG Luebeck, AS Popel, B Ribba, P Vicini, X Zhou, JA Weis, K Ye, GM Genin |
Annals of Biomedical Engineering | 2016 |
|
OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases
W Ji, C Arnst, AR Tipton, ME Bekier, WR Taylor, TJ Yen, ST Liu, Y Xue |
PloS one | 2016 |
|
KAOS: a new automated computational method for the identification of overexpressed genes
A Nuzzo, G Carapezza, SD Bella, A Pulvirenti, A Isacchi, R Bosotti |
BMC bioinformatics | 2016 |
|
Quantifying Kinase-Specific Phosphorylation Stoichiometry Using Stable Isotope Labeling In a Reverse In-Gel Kinase Assay
X Li, JT Cox, W Huang, M Kane, K Tang, CJ Bieberich |
Analytical Chemistry | 2016 |
|
Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature
MO Jacus, VM Daryani, KE Harstead, YT Patel, SL Throm, CF Stewart |
Clinical Pharmacokinetics | 2015 |
|
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd |
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | 2009 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)